Autologous Bone Marrow Transplantation in Relapses of Chemotherapy-Sensitive Aggressive Non-Hodgkin's Lymphoma: Long-Term Outcome

Authors: Lalle, M.; Montuoro, A.

Source: Journal of Chemotherapy, Volume 12, Number 5, 2000 , pp. 431-434(4)

Publisher: Maney Publishing

Buy & download fulltext article:

OR

Price: $25.00 plus tax (Refund Policy)

Abstract:

Eleven patients with relapsed intermediate to high grade non-Hodgkin's lymphoma (NHL) responding to induction treatment were treated with high-dose chemotherapy (CBV or ICBV conditioning regimen) plus autologous bone marrow transplantation as early consolidation treatment. At 6 years, relapse-free survival is 27.3% and overall survival is 36.4%. Patients with bone marrow involvement from NHL before the induction therapy did not have a worse prognosis. Despite the long-term follow-up, no secondary myelodysplasia or acute leukemia occurred in our patients. Within the limitations of patient number and selection, our retrospective study confirms the importance of tumor responsiveness and long-term follow-up. Patients with relapsed, but chemotherapy-sensitive NHL can achieve prolonged survival after high-dose chemotherapy plus autologous bone marrow transplantation.

Document Type: Research Article

Publication date: 2000-01-01

More about this publication?
Related content

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page